Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01

Table 4

Events and deaths in paediatric patients with ALL who were younger than 16 years of age and who were treated at the paediatric haematology service of the specialist “La Raza” IMSS Medical Centre.

Characteristic	Event				Death
	3 years		5 years		3 years		5 years
	No	Yes	No	Yes	No	Yes	No	Yes
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
Sex
Male	99 (59.3)	68 (40.7)	89 (53.3)	78 (46.7)	119 (71.3)	48 (28.7)	113 (67.7)	54 (32.3)
Female	78 (57.8)	57 (42.2)	72 (53.3)	63 (46.7)	91 (67.4)	44 (32.6)	83 (61.5)	52 (38.5)
Age (years)
<1	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (100)	0 (0)	1 (100)
1–5	79 (64.8)	43 (35.2)	71 (58.2)	51 (41.8)	93 (76.2)	29 (23.8)	87 (71.3)	35 (28.7)
5.1–9.99	35 (53.0)	31 (47.0)	32 (48.5)	34 (51.5)	44 (66.7)	22 (33.3)	40 (60.6)	26 (39.4)
≥10	63 (55.8)	50 (44.2)	58 (51.3)	55 (48.7)	72 (63.7)	41 (36.3)	69 (61.1)	44 (38.9)
Immunophenotype
B	166 (59.5)	113 (40.5)	150 (53.8)	129 (46.2)	198 (71.0)	81 (29.0)	185 (66.3)	94 (33.7)
T	11 (47.8)	12 (52.2)	11 (47.8)	12 (52.2)	12 (52.2)	11 (47.8)	11 (47.8)	12 (52.2)
WBC count (1 × 10^9/L)
<10	91 (61.9)	56 (38.1)	87 (59.2)	60 (40.8)	107 (72.8)	40 (27.2)	104 (70.7)	43 (29.3)
10–20	26 (54.2)	22 (45.8)	21 (43.8)	27 (56.3)	30 (62.5)	18 (37.5)	28 (58.3)	20 (41.7)
20–50	20 (58.8)	14 (41.2)	18 (52.9)	16 (47.1)	23 (67.6)	11 (32.4)	22 (64.7)	12 (35.3)
50–100	17 (63.0)	10 (37.0)	16 (59.3)	11 (40.7)	21 (77.8)	6 (22.2)	17 (63.0)	10 (37.0)
>100	23 (50.0)	23 (50.0)	19 (41.3)	27 (58.7)	29 (63.0)	17 (37.0)	25 (54.3)	21 (45.7)
Risk group
Standard	84 (57.5)	62 (42.5)	76 (52.1)	70 (47.9)	102 (69.9)	44 (30.1)	98 (67.1)	48 (32.9)
High	93 (59.6)	63 (40.4)	85 (54.3)	71 (45.5)	108 (69.2)	48 (30.8)	98 (62.8)	58 (37.2)